SCHEMBL5383365

SCHEMBL5383365

N[C@@H](Cc1ccccc1)[C@H](O)CNC1(Cc2cccc(Cl)c2)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ F2 P00734 3/20 0.40
▸ LMNA P02545 1/20 0.40
▸ PNMT P11086 1/20 0.40
▸ TACR1 P25103 2/20 0.39
▸ METAP2 P50579 1/20 0.38
▸ CSNK1E P49674 1/20 0.37
▸ KIF11 P52732 1/20 0.35
▸ SIGMAR1 Q99720 1/20 0.35
▸ GRIN2B Q13224 1/20 0.35
▸ HSD11B1 P28845 1/20 0.35
▸ MASP2 O00187 1/20 0.35
▸ HTR3E A5X5Y0 1/20 0.35
▸ HTR3B O95264 1/20 0.35
▸ HTR3A P46098 1/20 0.35
▸ HTR3D Q70Z44 1/20 0.35
▸ HTR3C Q8WXA8 1/20 0.35
▸ SPPL2A Q8TCT8 1/20 0.34
▸ CTSL P07711 1/20 0.34
▸ CTSB P07858 1/20 0.34
▸ CTSS P25774 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5224629 0.99 LMNA (0.42) F2LMNAPNMTTACR1METAP2
SCHEMBL5378900 0.95 F2 (0.39) F2LMNAPNMTTACR1METAP2
Hydrochloric Acid SCHEMBL5224811 0.94 LMNA (0.40) F2LMNAPNMTTACR1METAP2
SCHEMBL4690000 0.79 CSNK1E (0.49) F2CSNK1ESIGMAR1
Hydrochloric Acid SCHEMBL5221629 0.78 CSNK1E (0.48) F2CSNK1ESIGMAR1
SCHEMBL6892334 0.78 LMNA (0.61) F2LMNAPNMTMASP2
SCHEMBL4694678 0.78 MAPT (0.45) F2LMNAPNMTMETAP2CSNK1E
SCHEMBL3350317 0.78 LMNA (0.61) F2LMNAPNMTMASP2
SCHEMBL5218395 0.78 SLC2A1 (0.37) F2LMNAHSD11B1CTSLCTSB
SCHEMBL5388689 0.77 CSNK1E (0.53) F2CSNK1ESIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7253198-B2 Hydroxyethylamine derivatives for the treatment of Alzheimer's disease GLAXO GROUP LIMITED (GB) 2007-08-07 — — US disclosed
US-20060025459-A1 Hydroxyethylamine derivatives for the treatment of alzheimer's disease GLAXO GROUP LIMITED (GB) 2006-02-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060025459-A1 Hydroxyethylamine derivatives for the treatment of alzheimer's disease BACE2, PSEN2, BACE1 F2 4696/4885LMNA 1062/4885PNMT 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback